No Data
Express News | Regeneron Pharmaceuticals Inc - FDA Decision on This on Dupixent Expected by June 20, 2025
Express News | Dupixent® (Dupilumab) Sbla Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years
Wall Street Today: Trump Assigns Tariff Homework Study, Market Climbs
Live Stock News: Tariffs are so Back While Stocks Climb
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
I also think this is a great biopharmaceutical research and development company, I don't understand why it has been falling all the time.